Febuxostat does not significantly relieve the symptoms of foot pain in patients with gout, but it can reduce blood uric acid levels in patients with gout.
Febuxostat is a xanthine oxidase inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis. The drug is generally used for the long-term treatment of hyperuricemia in patients with gout, and is not recommended for hyperuricemia without clinical symptoms, but Febuxostat can not alleviate the symptoms of joint pain and swelling that occur in the attack period of patients with gout.
Taking Febuxostat in adequate amounts and on time to control blood uric acid concentration can help reduce the number of gout attacks and prevent complications such as gout stones and gouty nephropathy. Adverse drug reactions that may result from the use of Febuxostat include skin rash, joint pain, nausea, and liver function abnormalities.
Febuxostat should be used under the guidance of a physician, and it is recommended that patients with gouty foot pain go to the rheumatology and immunology department, orthopedics and other related departments in regular hospitals for detailed consultation.